🇺🇸 FDA
Patent

US 7902168

Compositions and methods for inhibiting expression of Nav1.8 gene

granted A61PA61P25/00A61P25/04

Quick answer

US patent 7902168 (Compositions and methods for inhibiting expression of Nav1.8 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P25/00, A61P25/04, A61P29/00, A61P43/00